SEATTLE, April 12, 2018 (GLOBE NEWSWIRE) — Atossa Therapeutics Inc. (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, announced today that is has fully enrolled the first of three cohorts in its Phase 1 study of its proprietary topical Endoxifen in…
SEATTLE, March 27, 2018 (GLOBE NEWSWIRE) — Atossa Therapeutics Inc. (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions today announced that Per Hall, MD, Ph.D., has been appointed as Scientific Advisor.Dr. Hall is widely regarded as a leading researcher…